OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA‐1273 vaccine in an 84‐year‐old female with polymorbidity and polypharmacy
Viola Schmidt, Roger Blum, Matthias Möhrenschlager
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 2
Closed Access | Times Cited: 12
Viola Schmidt, Roger Blum, Matthias Möhrenschlager
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 2
Closed Access | Times Cited: 12
Showing 12 citing articles:
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review
Yhojan Rodríguez, Manuel Rojas, Santiago Beltrán, et al.
Journal of Autoimmunity (2022) Vol. 132, pp. 102898-102898
Open Access | Times Cited: 79
Yhojan Rodríguez, Manuel Rojas, Santiago Beltrán, et al.
Journal of Autoimmunity (2022) Vol. 132, pp. 102898-102898
Open Access | Times Cited: 79
Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review
Elena Calabria, Federica Canfora, Massimo Mascolo, et al.
Pathology - Research and Practice (2022) Vol. 232, pp. 153834-153834
Open Access | Times Cited: 52
Elena Calabria, Federica Canfora, Massimo Mascolo, et al.
Pathology - Research and Practice (2022) Vol. 232, pp. 153834-153834
Open Access | Times Cited: 52
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
Carlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 42
Carlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 42
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis
Chanudda Washrawirul, Jidapa Triwatcharikorn, Jeerath Phannajit, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 1947-1968
Open Access | Times Cited: 39
Chanudda Washrawirul, Jidapa Triwatcharikorn, Jeerath Phannajit, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 1947-1968
Open Access | Times Cited: 39
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
Anna Pira, Jo Linda Sinagra, Francesco Moro, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Anna Pira, Jo Linda Sinagra, Francesco Moro, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Reply to “New‐onset bullous pemphigoid after inactivated Covid‐19 vaccine: Synergistic effect of the Covid‐19 vaccine and vildagliptin”
Carlo Alberto Maronese, Giovanni Di Zenzo, Giovanni Genovese, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Open Access | Times Cited: 11
Carlo Alberto Maronese, Giovanni Di Zenzo, Giovanni Genovese, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Open Access | Times Cited: 11
The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally
Irina Caplanusi, Agnieszka Szmigiel, Menno van der Elst, et al.
Drug Safety (2024) Vol. 47, Iss. 5, pp. 405-418
Open Access | Times Cited: 2
Irina Caplanusi, Agnieszka Szmigiel, Menno van der Elst, et al.
Drug Safety (2024) Vol. 47, Iss. 5, pp. 405-418
Open Access | Times Cited: 2
New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review
Po‐Chien Wu, I‐Hsin Huang, Ching-Ya Wang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 465-465
Open Access | Times Cited: 2
Po‐Chien Wu, I‐Hsin Huang, Ching-Ya Wang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 465-465
Open Access | Times Cited: 2
Initial results of the German ocular pemphigoid register
Rémi Yaïci, M. Roth, Gerd Geerling
Deleted Journal (2023) Vol. 120, Iss. 5, pp. 502-507
Closed Access | Times Cited: 2
Rémi Yaïci, M. Roth, Gerd Geerling
Deleted Journal (2023) Vol. 120, Iss. 5, pp. 502-507
Closed Access | Times Cited: 2
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review
Fabrizio Martora, Teresa Battista, Luca Potestio, et al.
Viruses (2024) Vol. 16, Iss. 12, pp. 1896-1896
Open Access
Fabrizio Martora, Teresa Battista, Luca Potestio, et al.
Viruses (2024) Vol. 16, Iss. 12, pp. 1896-1896
Open Access
Localized eczematous rash affecting left and right regions of breast and shoulder after Ad26.COV2.S vaccine against COVID-19 in a 30-year-old woman with comorbidities
Natalie Anasiewicz, Corsin Seeli, Marie‐Charlotte Brüggen, et al.
Allergo Journal International (2022) Vol. 32, Iss. 3, pp. 93-94
Open Access
Natalie Anasiewicz, Corsin Seeli, Marie‐Charlotte Brüggen, et al.
Allergo Journal International (2022) Vol. 32, Iss. 3, pp. 93-94
Open Access
